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Oncogenic PIK3CA mutations are found in a significant fraction of
human cancers, but therapeutic inhibition of PI3K has only shown
limited success in clinical trials. To understand how mutant PIK3CA
contributes to cancer cell proliferation, we used genome scale loss-
of-function screening in a large number of genomically annotated
cancer cell lines. As expected, we found that PIK3CAmutant cancer
cells require PIK3CA but also require the expression of the TCA
cycle enzyme 2-oxoglutarate dehydrogenase (OGDH). To under-
stand the relationship between oncogenic PIK3CA and OGDH func-
tion, we interrogated metabolic requirements and found an
increased reliance on glucose metabolism to sustain PIK3CA mu-
tant cell proliferation. Functional metabolic studies revealed that
OGDH suppression increased levels of the metabolite 2-oxogluta-
rate (2OG). We found that this increase in 2OG levels, either by
OGDH suppression or exogenous 2OG treatment, resulted in as-
partate depletion that was specifically manifested as auxotrophy
within PIK3CA mutant cells. Reduced levels of aspartate deregu-
lated the malate–aspartate shuttle, which is important for cyto-
plasmic NAD+ regeneration that sustains rapid glucose breakdown
through glycolysis. Consequently, because PIK3CA mutant cells ex-
hibit a profound reliance on glucose metabolism, malate–aspartate
shuttle deregulation leads to a specific proliferative block due to the
inability to maintain NAD+/NADH homeostasis. Together these ob-
servations define a precise metabolic vulnerability imposed by a re-
currently mutated oncogene.
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Mutations in PI3K, particularly those involving the catalyticsubunit PI3Kα, encoded by PIK3CA, are found in a num-
ber of cancer cell lineages, including breast, colorectal, endo-
metrial, and lung (1). PI3K signaling is normally activated in
response to membrane-bound receptor stimulation, which in
turn activates several effector molecules that ultimately promote
cell proliferation, survival, and motility (2). Mutations in PI3Kα
are clustered within the helical (E542K or E545K) or catalytic
(H1047R) domain, each of which leads to constitutive kinase
activation, hyperactive downstream signaling, and proprolifer-
ative cues. Expression of mutant PIK3CA in cell or animal
models induces tumorigenicity, confirming that these mutations
are oncogenic (3).
Multiple PI3K inhibitors have been developed, and both pan-
PI3K and PI3Kα-specific inhibitors are the subject of ongoing
clinical trials (4). To date, these inhibitors have only shown limited
clinical activity (5, 6). Because the mutant PI3Kα isoform appears
to be the key driver of tumorigenic phenotypes in genetically
engineered mouse models (2), development of mutation-specific
PI3Kα inhibitors may lead to improved outcomes.
Although it is clear that oncogenic PI3Kα drives hyperactivity
of normal downstream signaling cascades, accumulating evidence
indicates that these mutant alleles also exhibit additional activi-
ties. Specifically, oncogenic PI3Kα is thought to promote glycol-
ysis by enabling heightened glucose uptake through regulation of
GLUT1/4 protein translation (7) and subsequent plasma mem-
brane translocation (8), as well as regulating metabolite pathways
(9, 10). However, enhanced glycolysis is also observed in rapidly
proliferating cells, which requires increased glucose uptake (11).
Consequently, it has been difficult to discern how individual on-
cogenes affect metabolism, because proliferation alone has broad
impact on nutrient demand and utilization.
As an alternative to studies of candidate genes, genome-scale
loss-of-function screens offer an unbiased means to discover
novel and previously uncharted dependencies and functional
relationships in cells. Project Achilles is an effort to identify and
characterize cancer cell vulnerabilities by identifying gene de-
pendencies at genome-scale in a large number of human cancer
cell lines (12, 13). Using this dataset, we have focused on genes
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that are specifically required for proliferation or survival of cancer
cells that bear oncogenic PIK3CA mutations. This approach iden-
tified the tricarboxylic acid cycle (TCA) cycle enzyme 2-oxoglutarate
dehydrogenase (OGDH) as an essential requirement to maintain
PIK3CA mutant tumor cell proliferation or survival.
Results
Identification of OGDH as a Dependency Associated with PIK3CA
Mutation. To identify genes and pathways that are required in
cancer cells that harbor PIK3CA mutations, we used genome-
scale shRNA data from Project Achilles (12, 13). Specifically,
we used data derived from screening 17 PIK3CA mutant (MUT
class) and 68 PIK3CA wild-type (WT class) cell lines, where in-
dividual covariant shRNA values (from a pool of ≥5 shRNAs per
gene) were condensed to gene level dependencies using ATARiS
(14). We then performed a two-class (MUT vs. WT) comparison
among the two cell line classes by computing rescaled and nor-
malized mutual information (RNMI) scores using the PARIS
module in GenePattern (13) (Fig. 1A). To identify pathways or
cell processes that represent specific vulnerabilities in PIK3CA
MUT cells, we then performed Gene Set Enrichment Analysis
(GSEA) (15) using the highest probability ranked genes, which
revealed an enrichment for gene sets associated with the spli-
ceosome, the TCA cycle, and lysine degradation (Fig. 1B). As
expected, the gene with the highest association to the PIK3CA
MUT class was PIK3CA (12) (Fig. 1C and Dataset S1). Among
the 25 highest-ranked dependencies, we found all three compo-
nents of the OGDH complex, including OGDH, dihydrolipoamide
S-succinyltransferase (DLST), and dihydrolipoamide dehydroge-
nase (DLD) (Fig. 1 C and D) (16). OGDH is a highly conserved
TCA mitochondrial enzyme complex that catalyzes the irreversible
conversion of 2-oxoglutarate (2OG) and CoA-SH to succinyl–CoA
and CO2, while reducing NAD
+ to yield NADH (16).
To validate these observations, we individually assessed OGDH
(Fig. 2 and Fig. S1A), DLST (Fig. S2A), DLD (Fig. S2B), and
PIK3CA (Fig. 2 and Fig. S1A) as dependencies in multiple
PIK3CA MUT and WT cell lines. Using at least two individual
shRNAs per gene, we confirmed that these shRNAs suppressed
the expression of each of these genes independent of mutation
status (Fig. 2 and Figs. S1B and S2) and found that cell lines
harboring PIK3CA MUT uniquely depended on each of the
OGDH complex components for proliferation/survival.
OGDH Is Necessary to Maintain Mutant PIK3CA Tumor Growth in Vivo.
Because the genes and pathways used by cells grown in culture
may differ from genes required to sustain tumor growth in vivo,
we investigated whether OGDH suppression affects tumor
xenograft growth. We engineered PIK3CA MUT (RKO and
HCT116) and WT (LS411N and HT55) cancer cell lines to ex-
press doxycycline (dox)-inducible shRNAs targeting OGDH and
controls targeting GFP/RFP. Dox treatment induced shRNA
suppression of OGDH (Fig. S3 A and B) and inhibited the
proliferation of PIKC3A MUT cells in vitro (Fig. S3 C and D).
To validate that these observations were due to on-target effects
Fig. 1. Genome-scale loss-of-function analyses identify the OGDH complex
as a dependency in PIK3CAMUT cell lines. (A) Two-class comparative analysis
of combined gene-level shRNA scores (ATARiS values) between PIK3CA MUT
and WT cancer cell lines using PARIS module RNMI statistics for genes re-
quired for PIK3CAMUT cells (P < 0.01) used for (B) pathway identification by
GSEA (FDR < 0.25, P < 0.01) and (C) gene rank list of top 25 PIK3CA
mutation-associated dependencies. (D) Average ATARiS score sensitivity
among PIK3CAWT (n = 68) and MUT (n = 17) cell lines for PIK3CA and OGDH
(***P < 0.001; ****P < 0.0001 calculated using an unpaired two-sided t test).
Fig. 2. Differential effects of OGDH and PIK3CA suppression on PIK3CA
MUT and WT cell lines. (A and B) Matched immunoblot and proliferation
assays for PIK3CAMUT (A) and WT (B) cell lines following shRNA suppression
of OGDH and PIK3CA. Proliferation assays in the absence (blue bars) or
presence (red bars) of shRNA-selectable marker puromycin (puro). Prolifer-
ation data presented as the mean of four replicates + SD; P values calculated
using an unpaired two-sided t test (all shCONTROL vs. all shOGDH and
shPIK3CA; *P < 0.05, **P < 0.01, ***P < 0.001).














of these shRNAs, we generated and introduced a variant OGDH
cDNA allele (OGDH wobble) carrying silent mutations within
the targeting motifs for each of the three shRNAs (Fig. S3E).
Compared with controls, expression of this OGDH wobble allele
rescued the effects of the OGDH-specific shRNAs (Fig. S3F).
To investigate whether OGDH suppression induced a pro-
liferative arrest or cell death in PIK3CA MUT cells, we used the
fluorescent nucleic acid stain, SYTOX, which does not permeate
live cells, thus staining only dead cells. By quantifying SYTOX-
positive cells, we failed to detect cell death following OGDH
suppression (Fig. S3G). We confirmed these observations using
trypan blue staining of cells and quantifying cell numbers fol-
lowing shRNA induction (Fig. S3H). To assess whether OGDH
suppression affects the cell cycle, we performed BrdU labeling
experiments and found that PIK3CA MUT, but not WT, lines
exhibit a decrease in BrdU incorporation following OGDH sup-
pression (Fig. S3I), suggesting a block in the cell cycle, similar to
the effects of pharmacological PI3K inhibition (17).
To examine the requirement for OGDH for PIK3CA mutant
tumor growth, we implanted the dox-inducible cell lines into
immunocompromised mice and induced the expression of the
shRNAs either at time of implantation (Fig. 3 A–C) or subsequent
to tumor formation (Fig. 3 D–F). Confirming our in vitro obser-
vations, PIK3CA MUT xenografts displayed a significant sup-
pression of tumor growth upon OGDH shRNA induction (P <
0.01; Fig. 3 B and E), whereas suppression of OGDH had no ef-
fect on PIK3CA WT xenograft tumors (Fig. 3 C and F). Taken
together, these data indicate that OGDH is a genuine dependence
in PIK3CA mutant cancer cells supporting proliferation.
PIK3CA Mutant Cell Lines Display an Enhanced Requirement for
Glucose Metabolism. We next examined how OGDH function
affects PIK3CA mutant cancer cell proliferation. OGDH is an
integral component of the TCA cycle, and the PI3K/mTOR path-
way has been suggested to regulate both glucose (7, 8) and gluta-
mine metabolism (18, 19). Hence, we examined the dependence of
the PIK3CA MUT and WT lines on limiting availability of these
two nutrients. Although we found that glutamine deprivation
similarly affected proliferation of both PIK3CA MUT and WT
cells (Fig. 4A), reducing glucose availability preferentially affected
PIK3CAMUT cell line proliferation (Fig. 4B). These observations
clearly suggested that PIK3CA MUT cell lines exhibit a higher
Fig. 3. OGDH is an in vivo dependency in PIK3CA MUT cell lines. (A) Experimental strategy for B and C. Cancer lines expressing dox-inducible shRNAs were s.c.
injected into nude mice and dox was administered on the day of injection; longitudinal tumor growth was monitored over time. (B and C) PIK3CAMUT (B) and WT
(C) xenograft tumor growth following OGDH suppression. Error bars represent SEM for each point; n = 22–29 tumors per experimental cohort (all control tumors vs.
all shOGDH tumors). (D) Experimental strategy for E and F. Cancer cell lines expressing dox-inducible shRNAs were s.c. injected into nude mice and upon palpable
tumor formation dox was administered; longitudinal tumor growth was monitored over time. (E and F) Xenograft tumor growth of PIK3CA MUT (E) or WT
(F) cancer cell lines following induction of shRNAs after palpable tumor formation. Error bars represent SEM for each point; n = 19–26 tumors per experimental
cohort (all control tumors vs. all shOGDH tumors). P values calculated using an unpaired two-sided t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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glucose requirement to sustain proliferation, which is in agree-
ment with previous studies (8, 20). To confirm these findings, we
measured sensitivity to 2-deoxyglucose (2DG), a competitive in-
hibitor of the first step of glycolysis [conversion of glucose to
glucose-6-phosphate (G6P)] (Fig. 4C). We found that that the
PIK3CA MUT cell lines exhibited higher sensitivity to 2DG
compared with the WT cells, paralleling their requirement for
higher glucose concentration (Fig. 4B). Elevated glycolytic de-
mand could point toward reduced reliance on oxidative phos-
phorylation; therefore, we examined whether complex I inhibitors
rotenone and phenformin (Fig. S4 A and B), complex V/ATP
synthase inhibitor oligomycin A (Fig. S4A), and a mitochondrial
proton gradient uncoupler 2,4-dinitrophenol (2,4-DNP; Fig. S4C)
also affected proliferation. These inhibitors affected proliferation
nearly uniformly across the cell lines, but independent of PIK3CA
mutation status. In addition, we measured oxygen consumption
rates among PIK3CA MUT and WT cell lines (Fig. S4 D and E)
but failed to observe significant differences between the two
groups. Hence, it is unlikely that the sensitivity to OGDH sup-
pression in PIK3CA mutant cells is due to differences in mito-
chondrial bioenergetics but rather a consequence of their increased
reliance on glucose metabolism.
To investigate the source of differential nutrient use between
PIK3CA MUT and WT cell lines, we used [U-13C6]–glucose or
[U-13C5]–glutamine in media lacking the labeled nutrient. After
allowing cells to proliferate for 6 or 7 h, respectively, we per-
formed LC-MS to assess fractional labeling of metabolites. In
glutamine-labeled cells, we failed to find consistent differences in
steady-state glutamine-to-TCA flux between PIK3CA MUT and
WT cell lines (shOGDH-sensitive vs. resistant; Fig. S4 F and G).
This finding suggested that utilization or activity of OGDH re-
action did not explain the observed differential sensitivity to
OGDH suppression. In glucose-labeled cells, however, we ob-
served consistent increases in labeling along the three branches
downstream of G6P—glycolysis (pyruvate), pentose phosphate
pathway (adenosine and uridine), and nucleotide sugar metab-
olism (UDP-D-glucuronate; Fig. 4D and Fig. S5 A and B) across
the PIK3CA mutant cancer cell lines. In addition, total levels of
lactate were higher in MUT cells (with no significant difference
in fractional labeling; Fig. 4D), suggesting altered glucose utilization
and flux between pyruvate and lactate. We also found that secreted
lactate levels were consistently higher in the MUT cell lines com-
pared with WT measured over 72 h (Fig. 4E), as were their basal
extracellular acidification rates (ECAR; Fig. 4F). When we prop-
agated cells in the presence of the PIK3CA-specific catalytic in-
hibitor, BYL719 (21) at a dose that discriminates between PIK3CA
MUT and WT cell lines (Fig. S5C), we found that total levels of
glucose-derived metabolites involved in glycolysis and pentose
phosphate pathway were generally reduced in both MUT and
WT cells, with overall more potent effects in MUT cells (21) (Fig.
S5D). Collectively, these data suggest that PIK3CA MUT cancer
cells exhibit an enhanced requirement and utilization of glucose.
Effects of Suppressing OGDH on Metabolic Pathways. To examine
the metabolic consequences of OGDH suppression, we performed
LC-MS metabolite profiling following suppression of OGDH in
PIK3CA MUT and WT cells (Fig. 5 A and B). In both PIK3CA
MUT and WT cells, OGDH suppression resulted in a compa-
rable increase in the levels of its substrate, 2OG (Fig. 5C), and an
expected decrease in the pools of TCA cycle metabolites fumarate,
malate, and aspartate (Fig. 5D). Furthermore, several metabolites
involved in transamination reactions with 2OG (2-oxobutanoate,
phenylpyruvate and 2-ketoisovalerate), or products from reactions
that use 2OG (acetoacetate), were also affected. Expression of the
OGDH wobble allele (Fig. S3 E and F) reversed these changes
(Fig. S6 A–F).
In addition, we observed that the NAD+/NADH ratio was
reduced following OGDH suppression in the sensitive PIK3CA
MUT cells, indicative of an altered redox state that paralleled
sensitivity to OGDH (Fig. 5E). NADH produced in the cytosol
must be regenerated to NAD+ for glycolysis to proceed, which
can be achieved through the activity of lactate dehydrogenase
(22–24), glycerol-3-phosphate shuttle (25), or the malate–
aspartate shuttle. The malate–aspartate shuttle activity regenerates
NAD+ in the cytosol, which brings the reducing equivalents into
the mitochondria (26, 27) (Fig. 5F). The direct relationship be-
tween the malate–aspartate shuttle and OGDH is through the
substrate 2OG, which is consumed by transamination reactions on
both sides of the mitochondrial membrane (Fig. S7A) (27).
To specifically examine the effects of increasing 2OG levels
(Fig. 5C), we treated PIK3CA WT and MUT cells with a
membrane-permeable 2OG-ester derivative, dimethyl-(dm)-2OG
(28, 29) and assessed effects on cell proliferation. We confirmed
an increase in intracellular 2OG levels, and also decreased levels
of aspartate (Fig. 5G), both of which were comparable to what we
observed when we suppressed OGDH (Fig. 5 C and D). The levels
of malate and fumarate remained unaffected (Fig. S6 G and H),
consistent with cytosolic delivery of dm-2OG. In consonance with
these observations, we found that dm-2OG treatment potently
suppressed the proliferation of PIK3CAMUT cells, but had more
Fig. 4. PIK3CA MUT cells exhibit higher reliance on glucose. (A–C) Com-
parative proliferation effects among PIK3CA MUT (AGS, TOV21G, GP2D,
RKO, DLD1, HCT116, HT29) and WT (HT55, COV362, KM12, C2BBe1, LS411N)
lines propagated for 96 h in (A) reduced glutamine media (proliferation in
0.5 mM or no glutamine normalized to 8 mM glutamine); (B) reduced glu-
cose media (proliferation in 1 g/L normalized to 4.5 g/L); (C) 5 mM 2DG
(proliferation with 5 mM 2DG normalized to mock treated). (D) Ratio of total
and 13C-labeled pyruvate or lactate in MUT (HCT116, RKO, HT29) vs. WT
(HT55, C2BBe1, LS411N) cell lines. (E and F) Extracellular lactate levels (E) and
basal ECAR measurements (F) in PIK3CA MUT (HCT116, RKO, HT29) and WT
(HT55, C2BBe1, LS411N) cell lines. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001; P values were determined by a one-way ANOVA (A–C) or an
unpaired two-sided t test (D–F). Error bars represent SD of the mean of four
replicates (A–C, E, and F) or three replicates (D).














moderate effects on the WT cells (Fig. 5H). To confirm the
specificity of proliferative effects observed by dm2OG treatment,
we treated cells with two additional TCA cycle metabolite esters,
dimethyl succinate and diethyl malate, and did not observe dif-
ferential proliferative suppression among the MUT and WT
group (Fig. S6 I and J).
Because an increase in 2OG levels, either by shOGDH or dm-
2OG, preferentially affected PIK3CAMUT cell proliferation, we
examined whether transamination reactions linked to the malate–
aspartate shuttle were affected by these manipulations (Fig. 5F
and Fig. S7A). Specifically, we treated cells with aminooxyacetic
acid (AOA), a transaminase inhibitor that exhibits some pref-
erential inhibition of aspartate transaminase (Fig. 5F) (27, 30)
and subsequently assessed effects on cell proliferation. We found
that AOA preferentially suppressed proliferation of the PIK3CA
MUT cells (Fig. 5I). In addition, low-dose AOA sensitized
PIK3CAWT cell lines to OGDH suppression (Fig. S6 K and L),
indicating that further decrease in aspartate transaminase-mediated
oxaloacetate-to-aspartate transamination affects OGDH sensitivity
as observed in PIK3CA MUT cells. Together, these data show
that OGDH suppression causes an expected increase in the levels
of 2OG, accompanied by a decrease in the levels of downstream
TCA cycle metabolites, as well as a concomitant reduction in
NAD+/NADH ratios. These changes are consistent with an al-
tered redox state that can be explained as a consequence of
malate–aspartate shuttle transamination reaction inhibition driven
by increased 2OG levels (Fig. 5F).
OGDH Suppression Results in Malate and Aspartate Insufficiency. To
gain further insight into acute metabolic changes following OGDH
suppression, we performed a 3-h pulse with [U-13C6]–glucose
tracer in PIK3CA WT and MUT cells to assess effects on
glucose-derived metabolites (Fig. S5A). We found that labeled
glucose-derived lactate and glyceraldehyde-3-phosphate were
reduced specifically in PIK3CA MUT cells following OGDH
Fig. 5. Metabolic effects following OGDH suppression. (A) Venn diagrams depicting overlapping metabolite level changes following OGDH suppression in
PIK3CAWT (HT55, C2BBe1) and MUT (RKO, HT29) cell lines. (B) Schematic of the TCA cycle with emphasis on overlapping metabolites whose levels are altered
following OGDH suppression (blue, decreased; red, increased). (C–E) Relative levels of 2OG (C), malate, fumarate, and aspartate (D), or NAD+/NADH ratio
(E) following OGDH suppression. (F) Schematic representation of the cytoplasmic–mitochondrial malate–aspartate shuttle that regenerates cytoplasmic NAD+
to enable glycolysis to proceed. (G) MS analysis of metabolite changes in PIK3CAWT (C2BBe1, COV362, LS411N, HT55) or MUT (TOV21G, DLD1, HCT116, HT29)
lines mock treated or propagated in 7 mM dm-2OG for 72 h; relative levels (normalized to mock treated) of 2OG and aspartate are shown; H. Proliferation
effects in PIK3CAWT (C2BBe1, KM12, HT55, LS411N, COV362) and MUT (HT29, GP2D, TOV21G, RKO, HCT116, DLD1) lines following 96 h treatment with 7 mM
dm-2OG. (I) Proliferation effects in PIK3CA WT (C2BBe1, KM12, HT55, LS411N, COV362) and MUT (AGS, HT29, GP2D, TOV21G, RKO, HCT116, DLD1) lines
following 96-h treatment with 1.75 mM AOA. OA, oxaloacetate; Succ-CoA, succinyl-CoA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P values were
determined by an unpaired t test with Welch’s correction (C–E and G) or a one-way ANOVA with multiple comparisons (H and I). Error bars represent SD of the
mean of three (C–E and G) or four replicates (H and I).
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suppression (Fig. S6 M and N), suggestive of impaired glycolytic
flux. As an alternative means to examine the effects on glutamine-
derived metabolites, we also used a 7-h pulse with [U-13C5]–glu-
tamine to label cells (Fig. 6A and Fig. S4F). We found that C5-
glutamine incorporation was increased upon OGDH suppression
(Fig. S6O), suggesting increased reliance on glutamine anaplerosis
to sustain the TCA cycle and a shift toward elevated gluta-
minolysis. As expected, we found a marked increase in total 2OG
levels upon OGDH suppression (Fig. 6B), accompanied by a 30–
50% decrease in one-, two-, and three-carbon labeled (C1, C2, and
C3) fractions of 2OG in MUT cells (Fig. 6C). Furthermore, we
observed a shift toward reductive carboxylation of 2OG toward
citrate, reflected in an increase in the C5-labeled fraction, in both
of the MUT cell lines, but only one of the WT lines, LS411N (Fig.
S6P) (31). Despite the threefold increase in C5-labeled citrate
observed in MUT cells, this species constituted only ∼1–6% of
total citrate, suggesting that this alternate path of glutamine-
derived carbons likely does not explain sensitivity to OGDH sup-
pression. In agreement with our previous experiments (Fig. 5D), we
confirmed the reduction in total malate levels in PIK3CA MUT
cells upon OGDH suppression (Fig. S6Q), with more potent re-
duction in the C1 and C2 fractions in MUT cells (Fig. 6D). We also
confirmed reduction in total aspartate levels (Fig. 5D and Fig.
S6R), accompanied by more potent decrease in labeled species in
MUT cells (Fig. 6E).
OGDH Suppression Induces Aspartate Auxotrophy in PIK3CA Mutant
Cells. Given the profound and consistent decrease in aspartate
levels caused both by OGDH suppression (Fig. 5D and Fig. S6R)
and exogenous 2OG (Fig. 5G), we considered whether depletion
of this amino acid following OGDH suppression drives the ob-
served sensitivity in PIK3CAMUT cells. Aspartate is a nonessential
Fig. 6. Aspartate supplementation reduces sensitivity to OGDH suppression or 2OG treatment. (A) Diagram of anaplerotic glutamine flux into the TCA cycle,
depicting both oxidative and reductive pathways of aspartate generation from 2OG. Filled circles depict 13C atoms originating from [U-13C5]–L-glutamine.
(B–E) MS analysis in PIK3CAMUT (HCT116 and RKO) and WT (HT55 and LS411N) cell lines cultured in the presence of dox for 72 h and with [U-13C5]–glutamine
for 7 h; total pool sizes for 2OG (B) are shown separately from fractions of glutamine-derived labeled 2OG (C), malate (D), and aspartate (E). (F) Proliferation
assay for PIK3CA MUT cell lines (HCT116 and RKO) expressing dox-inducible shRNAs, without or with ectopic SLC1A3, 96 h post dox induction of shRNAs and
concurrent addition of L-aspartate. (G) Proliferation of PIK3CA MUT cell lines (RKO and HCT116) overexpressing SLC1A3, in the presence of 10 mM aspartate
and mock treated or treated with 5 mM dm-2OG for 96 h. (H and I) MS analysis of aspartate in PIK3CA MUT cell line RKO expressing dox-inducible shRNAs,
without or with ectopic SLC1A3. Cells were cultured in the presence of dox with or without 5 mM L-aspartate or 1 mM sodium pyruvate for 72 h and with
[U-13C5]–glutamine for 7 h. Total pool sizes for aspartate (H) are shown separately from fractions of glutamine-derived labeled aspartate (I). (J) MS analysis of
NAD+/NADH ratios in PIK3CAMUT cell line RKO. Cells were cultured in the presence of dox with or without 5 mM L-aspartate for 72 h. Each bar represents the
mean + SD of three (B–E and H–J) or four (F and G) replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P values were determined by unpaired two-
tailed t-test statistics with Welch’s correction for unequal variance (B–E), unpaired two-tailed t test (G), or a one-way ANOVA (F and H–J).














amino acid that is generated in the cell through 2OG-dependent
transamination to and from oxaloacetate (Fig. S7A). Following
OGDH suppression in PIK3CA MUT cells, reduced aspartate
levels (Fig. 5D and Fig. S6R) could be caused by mitochondrial
2OG accumulation and matrix-side malate–aspartate shuttle
deregulation (Fig. 5F) (32), and conversely exogenous 2OG ad-
dition would result in the same changes but initiated on the cy-
toplasmic side. Interestingly, in mitochondrial respiration deficient
cells, or in the presence of complex I inhibitor phenformin, as-
partate supplementation was recently shown to support cell pro-
liferation and bypass oxidative phosphorylation inhibition as
well as genetic defects in mitochondrial DNA (33, 34). To assess
whether aspartate supplementation could reduce sensitivity to
OGDH suppression, we used high-dose aspartate supplemented
media and measured cell proliferation. We found that exogenous
addition of aspartate could not restore proliferation (Fig. S7B).
This result was, however, not surprising, given that most tissues
outside the CNS do not normally express aspartate transporters
at the plasma membrane (33). However, ectopic expression of
the aspartate/glutamate transporter, SLC1A3 (33) (Fig. S7C), in
combination with aspartate supplementation, caused a robust and
dose-dependent sensitivity decrease to OGDH suppression (Fig.
6F). Furthermore, overexpression of SLC1A3 in the presence of
exogenous aspartate reduced sensitivity to exogenous dm-2OG
(Fig. 6G), suggesting that intracellular 2OG increases drive dif-
ferential OGDH sensitivity. Notably, pyruvate supplementation
following OGDH suppression did not reduce sensitivity (Fig.
S7D), likely because aspartate generated from oxaloacetate, which
originates from malate or anaplerotically from pyruvate, requires a
transamination that is imbalanced due to excess 2OG (Fig. S7A).
Aspartate Supplementation Restores a Truncated TCA Cycle. To as-
sess which metabolic pathways were restored by aspartate sup-
plementation, we performed [U-13C5]–glutamine tracer experiments
(Fig. 6A and Fig. S4F). As expected, we confirmed that aspartate
and malate levels were restored following aspartate, but not
pyruvate, addition (Fig. 6 H and I and S7G), whereas 2OG and
succinate levels remained elevated and depleted, respectively
(Fig. S7 E and F). In addition, aspartate supplementation re-
stored the NAD+/NADH ratio upon OGDH suppression to that
of unperturbed control (Fig. 6J). These observations collectively
indicate that the shOGDH-induced truncation of the TCA cycle
causes 2OG to deplete malate and aspartate, both because of the
effects on the TCA cycle but also due to affecting the operation
of the malate–aspartate shuttle. Because of its important role in
NAD+ regeneration for sustained glycolysis and maintained
building-block synthesis, the malate–aspartate shuttle function is
more critical for PIK3CA mutant cancer cell lines (Figs. 5F and 7
and Fig. S7H), leading to differential dependency on OGDH
function to maintain intracellular 2OG balance.
Discussion
Mutations in metabolic genes, such in IDH1/2 (35), fumarate
hydratase (36), succinate dehydrogenase (37, 38), and mitochondria-
encoded genes (39), although relatively rare, are actively pursued for
therapy because of their causal involvement in the tumors that
carry those lesions. In addition, hallmark oncogenes such as
KRAS (40, 41) and MYC (42), as well as the mTORC1 pathway
(18), provoke unique metabolic dependencies when hyperactivated.
Because of their frequent involvement in promoting cancer devel-
opment and growth, these dependencies are therefore being con-
sidered for improving cancer treatment.
From genome-scale vulnerability screens, we have identified
the mitochondrial TCA cycle enzyme OGDH as a specific vul-
nerability in PIK3CA mutant cancer cells, required both for
proliferation in culture, as well as in vivo tumor maintenance
(Fig. S3 and Fig. 3). The PI3K pathway has previously been as-
sociated with multiple roles in metabolism, involving heightened
glucose import through regulation of GLUT1 expression; GLUT4
translation and membrane localization (7, 8); stimulation of glu-
tathione synthesis (43); and suppression of β-oxidation (9). In our
analyses, and akin to previous reports (44), PIK3CA mutant cells
do not exhibit altered reliance on mitochondrial metabolism (Fig.
S4), suggesting an alternative requirement for OGDH, other than
its role in the TCA cycle.
Using metabolomic and pharmacological approaches, we found
that PIK3CA mutant cancer cells rely on OGDH through main-
taining appropriate levels of the substrate 2OG. Following in-
hibition of OGDH, 2OG levels are increased (Figs. 5C and 6B),
whereas the levels of malate and aspartate decrease (Fig. 5D and
Fig. S6Q and R), which in PIK3CAmutant cells reduces the NAD+/
NADH ratio (Fig. 5E and Fig. S6F). In keeping with these results, it
was recently reported that certain cancer cell lines depend on
OGDH activity for aspartate and function of the malate–aspartate
shuttle (45); however, without any association with tumor cell
mutation status. The glycolytic nature of PIK3CA mutant cells,
reflected in their reliance on glucose (Fig. 4B), sensitivity to in-
hibition of glycolysis (Fig. 4C), and elevated secretion of lactate
(Fig. 4 E and F), collectively imparts sensitivity to excess 2OG levels
via deregulation of malate–aspartate shuttle activity, an important
NAD+ regeneration pathway in the cytoplasm (Fig. 5F). Our ob-
servations suggest that dependence on OGDH activity is increased
in cells with elevated glucose demand. Thus, we provide mecha-
nistic insight into why a defined subset of cancer cell lines are more
dependent on OGDH function through their heightened reliance
on 2OG maintenance, which closely associates with the highlighted
role of PIK3CA in promoting anabolic metabolism (7–10).
Inherent stress from uncontrolled cancer cell growth provokes
metabolic insufficiencies that must be satisfied by alternative nu-
trient uptake for TCA cycle catabolism, which involves β-oxidation
of lipids, increased glutaminolysis, and breakdown of extracel-
lular proteins. To this end, PIK3CA mutant colorectal cancer cell
lines were recently shown to up-regulate the glutamate pyruvate
transaminase 2 (GPT2) to fuel the TCA cycle with 2OG gener-
ated from pyruvate and glutamate (46). Notably, this role for
GPT2 within PIK3CA mutant colon cancer cells was determined
under glutamine depletion; this represents an alternative path-
way for pyruvate and glutamate to sustain the TCA cycle that
would parallel the widely appreciated anaplerotic roles of pyru-
vate to generate oxaloacetate through pyruvate carboxylase and
glutamate dehydrogenase to generate 2OG. In our experi-
ments, conducted in complete media, OGDH suppression or
exogenous 2OG addition, we failed to find deregulation of the
TCA cycle attributable to PIK3CA mutation (Fig. 5G and Fig.
S6 G and H). Importantly, we found that the effects of OGDH
suppression or 2OG treatment were alleviated by increasing in-
tracellular levels of aspartate using aspartate/glutamate trans-
porter overexpression and exogenous aspartate supplementation
Fig. 7. Model depicting increased requirement of PIK3CAMUT cell lines for
unperturbed operation of the malate–aspartate shuttle to satisfy their
heightened glycolytic needs for NAD+ regeneration. OGDH suppression
causes 2OG increase, which in turn depletes aspartate availability, causing a
disruption in malate–aspartate shuttle operation.
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(Fig. 6 F and G). Aspartate supplementation following OGDH
suppression, however, did not restore the levels of the TCA cycle
metabolites 2OG and succinate (Fig. S7 E and F), but restored
the NAD+/NADH ratios (Fig. 6J) and cell proliferation (Fig. 6
F–I and Fig. S7 G and H). These observations suggest that it is
the effects of elevated 2OG on depleting aspartate, rather than
general suppression of the TCA cycle, that represents a unique
vulnerability in PIK3CA mutant cells.
We speculate that pyruvate anaplerosis via oxaloacetate does
not occur because aspartate is made from oxaloacetate, and this
reaction is opposed by elevated 2OG (Fig. S7A). Because PIK3CA
mutant cell lines require NAD+ regeneration due to their inability
to regulate glycolytic flux, our findings point toward 2OG imbal-
ance as a critical metabolic sensitivity in this class of cancers. Al-
though aspartate is integral to the operation of the malate–
aspartate shuttle, we note that it is also a required metabolite for
additional metabolic pathways, including the urea cycle (47); nu-
cleotide synthesis (48–50); arginine (51) and asparagine synthesis
(52); glutamate metabolism (53); and protein synthesis (54).
Hence, it is possible that additional pathways in the PIK3CAMUT
cancers also require aspartate for sustained proliferation.
2OG mimetic tool compounds have been shown to have
antiproliferative activity in a small set of cancer cell lines, albeit
at high doses (mM) (55), making it difficult to extend these
studies to animal models. Nevertheless, our observations suggest
that further development of these or similar compounds may
have potential therapeutic value if toxicity that may be caused by
OGDH inhibition can be tolerated due to the reported association
between its reduced activity and neurodegenerative disorders (56).
As an alternative to OGDH inhibition, several recent studies have
shown that aspartate becomes limiting for cancer cells bearing
mutations in succinate dehydrogenase or under conditions of
electron transport chain (ETC) suppression, suggesting inhibition
of aspartate synthesis as a potential therapeutic strategy in those
cancers (33, 34, 38). Furthermore, NAD+ depletion has been ex-
plored as a therapeutic option in certain subsets of cancer (57),
including IDH1 mutant gliomas, which critically depend on NAD+
availability (58).
Collectively, our observations indicate that oncogenic PIK3CA
confers a metabolic state that makes cells more sensitive to el-
evated levels of 2OG, revealing a heightened dependency on
aspartate to maintain the malate–aspartate shuttle support for
NAD+ regeneration. Further experimental exploration to assess
aspartate synthesis, the operation of the malate–aspartate shuttle,
or NAD+ regeneration may offer valuable prognostic or thera-
peutic insights for cancers bearing mutations in PIK3CA. Im-
portantly, these observations may extend to other tumors that do
not bear mutations in PIK3CA, but display a heightened glycolytic
use and reliance on efficient NAD+ regeneration. In fact, when
we analyzed data from Project Achilles (Fig. 1) we found that
other cancer cell lines display sensitivity to OGDH suppression,
and it remains to be determined which genetic features drive this
dependency. It is plausible that these tumors generally display an
increased glycolytic drive and would therefore exhibit comparable
vulnerability to increases in 2OG levels. Alternatively, because of
the dynamic plasticity of cancer cell metabolism, we could also
envision that cell lines that initially exhibited sensitivity to 2OG
fluctuation or OGDH suppression could acquire resistance to
these insults. One way to achieve resistance would be by a met-
abolic shift toward increased oxidative metabolism, which would
be more glucose efficient, and thus render reduced reliance on
the malate–aspartate shuttle for NAD+ regeneration. Hence to
prevent therapeutic resistance, cotargeting metabolic pathways
involving mitochondrial metabolism may be advantageous, and
would represent a confluence of pharmacological opportunities.
Materials and Methods
Code Availability.
PARIS. The GenePattern module PARIS (13) (https://www.broadinstitute.org/
achilles/resources) was used for RNMI statistics to generate a list of genes that
are preferentially required for proliferation of PIK3CA MUT cell lines com-
pared with WT cell lines (Dataset S1). The ATARiS (14) gene level dataset
v2.0 was used as a data file (www.broadinstitute.org/achilles/). The mutation
annotation file used as classifier was generated using hybrid capture mutation
data from the data from the Cancer Cell Line Encyclopedia (https://www.
broadinstitute.org/ccle). A total of 85 cell lines (17 PIK3CA MUT) were used in
the analysis, where cell lines without PIK3CA mutation data were removed.
GSEA. GSEA (15) using KEGG 4.0 database was performed on the list of genes
identified as required for the survival of PIK3CA MUT cell lines using PARIS
two-class comparison analysis (13) with the significance cutoff of P < 0.01
among PIK3CA MUT-associated dependencies. GSEA was performed with
10,000 permutations and a threshold of at least three genes per gene set.
PARIS, ATARiS, and GSEA are publicly available as GenePattern modules
(https://genepattern.broadinstitute.org/).
Cell Proliferation Assays. Proliferation assays in the presence of shRNAs were
performed in 24-well tissue culture dishes where cells were seeded at 10,000–
20,000 cells per well. The following day duplicate plates were infected with
lentivirus (shRNA); each plate contained four replicate wells for each of the
shRNAs used. At 1 d postinfection, one of the duplicate plates was treated
with puromycin (selectable marker for shRNAs), and the other plate was
refed with fresh media alone. At 4–5 d after infection, plates were fixed with
10% acetic acid/10% ethanol, followed by staining with 0.4% crystal violet/20%
ethanol, washed, dried, and then incorporated dye extracted (10% acetic acid)
for 96-well format density readings (OD at 595 nm) as a measure of corre-
sponding cell numbers. Fold change in cell numbers was calculated by normal-
izing to final number of cells in uninfected wells in the absence of puromycin.
When doxycycline-inducible shRNAs were used, the proliferation assays were set
up similarly, except that doxycycline (0.1 or 1 μg/mL) was added 1 d after
seeding, and crystal violet assays performed 96 h after doxycycline addition.
Proliferation assays in the presence of various chemicals or in different
growth conditions (e.g., low vs. high nutrients) were performed in the same
way, but in the absence of puromycin selection. All drug treatments and
nutrient deprivation assays were performed for 96 h. Proliferation assay
results are shown as mean values with error bars representing SD from the
mean; Student’s two-sided t test was used to calculate P values for experi-
mental two-class comparisons or a one-way ANOVA for multiple compari-
sons. All proliferation assays were repeated at least three times.
Immunoblotting. Protein lysates were resolved on 7.5 or 8–16% polyacrylamide
SDS gels (Bio-Rad), transferred onto nitrocellulose membranes (Bio-Rad) using
standard wet-transfer procedures, and incubated with primary antibodies as
indicated. All immunoblot assays were visualized using a LiCOR Odyssey in-
frared imager. Quantification of immunoblot signal was performed using
LiCOR Odyssey software. For each measurement of signal intensity, the
OGDH and α-tubulin signals were adjusted for each lane’s background
fluorescence, followed by normalization of background-adjusted OGDH
signal to background-adjusted α-tubulin signal from the same lane.
Animal Experiments. All animal experiments were conducted under animal
protocol approved by the Dana-Farber Cancer Institute Institutional Animal
Care and Use Committee and in accordancewith NIH guidelines. Six-week-old
male homozygous NCR-Nu mice (Taconic) were used for xenograft experi-
ments. Briefly, human cancer cell lines expressing dox-inducible shRNA
constructs or uninfected human cancer cell lines were injected at three sites
each per animal (using 2,000,000 cells per site). Each shRNA cohort contained
five mice (maximum 15 tumors per cohort total), based on estimates to reach
statistical significance of 80% power in the experiment for at least twofold
difference in size and less than 25% SD. Each of 10 animals per experimental
group (CONTROL or shOGDH, five animals per individual shRNA) was injected
at three injection sites; injection sites that never formed tumors were ex-
cluded from the analysis. Dox was administered through food either on the
day of injection or upon palpable tumor formation (7–10 d after injection).
Tumor size was measured using calipers twice weekly. Tumor size was nor-
malized to initial tumor size on the first day of dox treatment and expressed
as percentage of initial size (with initial size set to 100%), or alternatively for
initial treatment, represented as direct measured tumor volumes [length ×
length × width/2 (mm)]. For all animal experiments, statistical significance
was calculated using two-sided Student’s t-test statistics among two exper-
imental groups: shCONTROL (includes uninfected and shRFP) and shOGDH














(includes shOGDH 1714 and 2497); significance of individual experiments is
denoted on corresponding graphs using P values, with P > 0.05 considered
not significant (n.s.). Sample sizes for each experimental group are as fol-
lows. Fig. 3B, RKO: CONTROL n = 29 tumors; shOGDH n = 27 tumors. Fig. 3C,
LS411N: CONTROL n = 22 tumors; shOGDH n = 25 tumors. Fig. 3E, RKO:
CONTROL n = 26 tumors; shOGDH n = 26 tumors. Fig. 3E, HCT116: CONTROL
n = 23 tumors; shOGDH n = 24 tumors. Fig. 3F, LS411N: CONTROL n =
21 tumors; shOGDH n = 19 tumors. Fig. 3F, HT55: CONTROL n = 24 tumors;
shOGDH n = 25 tumors.
Materials. The following antibodies were used: OGDH (HPA020347), DLST
(SAB1412704, clone 4D7) and α-tubulin (T9026, clone DM1A) from Sigma
Aldrich; p110α (4255) and GAPDH (5174) from Cell Signaling; DLD (sc-
365977) and SLC1A3 (C-19) from Santa Cruz; secondary anti-rabbit and
anti-mouse IRDye antibodies from LiCOR. Lentiviral shRNAs were obtained
from The RNA Consortium (TRC), Broad Institute. Complete sequence in-
formation for all shRNA constructs used can be found at the TRC website
www.broadinstitute.org/rnai/public/.
Human SLC1A3 cDNA was in a pMXs vector backbone and had been
previously described (33).
The following chemicals were used: L-glutamine, sodium pyruvate (Life
Technologies); doxycycline (at final concentration of 0.1 or 1 μg/mL; Clon-
tech); 2-deoxyglucose, dimethyl-2-oxoglutarate, dimethyl succinate, diethyl
malate, aminooxyacetic acid, rotenone, oligomycin, antimycin A, phenformin,
2,4-dinitrophenol, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP), L-aspartic acid (Sigma Aldrich).
The following TRC shRNAs were used: shPIK3CA 2145 TRCN0000039607
(GCTCATTAACTTAACTGACAT); shPIK3CA 3234 TRCN0000010407 (AATGA-
AAGCTCACTCTGGATT); shOGDH 1714 TRCN0000220904 (CCTGAGTATGAG-
GAGGAAATT); shOGDH2497 TRCN0000220905 (GAAGCCAACTTCGACATCAAT);
shOGDH 2956 TRCN0000220907 (GACTACGTGAAGCCAAGACTT); shLacZ
TRCN0000072231 (CGCTAAATACTGGCAGGCGTT); shLUC TRCN0000072254
(ATGTTTACTACACTCGGATAT); shGFP TRCN0000072186 (TGCCCGACAACC-
ACTACCTGA); and shRFP TRCN0000072212 (CCGTAATGCAGAAGAAGACCA).
The dox-inducible shRNA vector backbone was previously described (59),
whereby the inducible shRNAs were generated by cloning annealed hairpin
oligos into the AgeI/EcoRI site of pLKO-TO.puro. The OGDH wobble mutant
overexpression construct was generated by site-directed mutagenesis of the
OGDH wild-type cDNA [obtained from the human ORFeome collection
(horfdb.dfci.harvard.edu/hv7/), internal ID 3630] in the pDONR.223 vector
(Invitrogen). Five mutations were inserted per targeting shRNA, resulting in
15 total conservative nucleotide substitutions. We used the following primers
for site-directed mutagenesis: 1714_TOP: ggtcaaccagcctgaAtaCgaAgaAga-
Gatttccaagtatgat; 1714_BOTT: atcatacttggaaatCtcTtcTtcGtaTtcaggctggttgacc;
2479_TOP: gccagaccttaaagaGgcAaaTttTgaTatcaatcagctatat; 2479_BOTT: ata-
tagctgattgatAtcAaaAttTgcCtctttaaggtctggc; 2956_TOP: aggctactatgactaTgtA-
aaAccGagGcttcggaccaccatc; and 2956_BOTT: gatggtggtccgaagCctCggTttTacA-
tagtcatagtagcct.
Using the Gateway LR reaction (Invitrogen), the wobble OGDH cDNA was
moved to pLenti6.3/V5 destination vector (Invitrogen), which was used for
subsequent lentivirus production. All cDNA expression constructs are de-
posited to Addgene.
Cell Culture. The following human cancer cell lines were used: HT29, T47D,
MDA-MB-453, KM12, HT55, C2BBe1, RKO, GP2D, DLD1, MCF7, SF767, AGS,
SKCO1, LS411N, COV362, IGR39, Kuramochi, HCT116, TOV21G, and SU.86.86.
These cell lines were obtained from The Cancer Cell Line Encyclopedia (CCLE) -
https://www.broadinstitute.org/ccle/home and were originally acquired by
CCLE from multiple commercial vendors. Before their use in Project Achilles
and subsequent validation experiments, all cell lines were tested for myco-
plasma contamination and SNP fingerprinted to confirm their identity (60).
All cell lines were cultured in DMEM containing 4.5 g/L glucose (unless in-
dicated otherwise), L-glutamine, and sodium pyruvate (Life Technologies
11995-073), supplemented with penicillin/streptomycin, L-glutamine (4 mM),
and 10% FBS. Cell line derivatives expressing dox-inducible shRNAs were
cultured in the same media but supplemented with Tet-System Approved
FBS from Clontech (tetracycline-free). In experiments in which cells were
grown in low glucose (1 g/L) or in reduced or no glutamine, DMEM low
glucose (Life Technologies 11885-084) or DMEM no glutamine (Life Tech-
nologies 10313-021) were used, respectively.
Stable Cell Lines. Cell lines with stable expression of cDNA or shRNAs were
generated using lentiviral delivery vectors. Cells were grown on six-well dishes
and infected with lentiviruses at high multiplicity of infection. The following
day the cell media was replaced with fresh media, trypsinized, transferred to a
10-cm dish and selected with puromycin or blasticidin the day after.
Metabolite Profiling and Analysis and Glucose Isotope Tracing. Metabolite
extraction was performed as described previously (61). In brief, cells were
cultured in log growth phase on 10-cm dishes to ∼70–80% confluence. Two
hours before metabolite extraction, cells were refed with fresh media. Cells
were then washed with PBS at 37 °C, followed by metabolite extraction by
scraping in 80% methanol (on dry ice), insoluble materials collected, two
sequential extractions combined and stored at −80 °C. For extracellular
lactate quantification, cells were propagated in pyruvate-free media on six-
well dishes and at indicated time points following initial refeeding 30 μL of
media was harvested per well per sample. Subsequent extracellular metab-
olite extraction was performed on dry ice by adding methanol to final
concentration of 80%, followed by centrifugation to remove insoluble ma-
terials (61). Before mass spectrometry, the metabolite extracts were lyoph-
ilized, resolubilized in 20 μL of LC/MS grade water, and then analyzed by
liquid chromatography tandem mass spectrometry using positive ion/nega-
tive ion polarity switching via selected reaction monitoring on a 5500 QTRAP
hybrid triple-quadrupole mass spectrometer (AB/SCIEX), as previously de-
scribed (61). Peaks were integrated using MultiQuant 2.1 data analysis
software (AB/SCIEX). Metabolite differences were analyzed by normalizing
samples by total levels and comparing replicate samples in groups that
satisfy significance of P < 0.05 [unpaired two-sided t test with Welch’s cor-
rection for unequal variance (for two groups) or a one-way ANOVA with
multiple comparisons (for more than two groups)].
Glucose isotope tracing was conducted following the same protocol as for
unlabeled metabolite profiling. Cells were incubated in regular media for
24 h and then refed withmedia containing unlabeled 2.25 g/L glucose (half of
standard glucose concentration normally used) 24 h before harvesting me-
tabolites. For baseline comparison among cell lines, the media was supple-
mented with 2.25 g/L [U-13C]–glucose 6 h before metabolite isolation. For
experiments with dox-inducible OGDH suppression, cells were incubated in
the presence of dox for 48 h and refed with media containing dox and
unlabeled 2.25 g/L glucose for another 24 h. At 3 h before harvesting me-
tabolites, the media was supplemented with 2.25 g/L [U-13C]–glucose.
Glutamine Isotope Tracing. Glutamine isotope tracing was conducted on a
QExactive benchtop Orbitrap mass spectrometer equipped with an Ion
Max source and a HESI II probe, coupled to a Dionex UltiMate 3000 UPLC
system (Thermo Fisher Scientific). Cells were incubated in the presence of dox
for 72 h and refed with glutamine-free DMEM media supplemented with
1 mM [U-13C5]–glutamine 7 h before harvesting polar metabolites with 80%
methanol (with 10 ng/mL valine-d8 as internal standard). Following 10 min
vortex at 4 °C and a 10 min spin at 20,800 × g, samples were dried under
nitrogen gas and resuspended in 100 μL water for analysis. Analysis was
performed as previously described (33).
Bioenergetic Profiling. Oxygen consumption rate (OCR) and ECAR of intact
cells were measured using an XF24 Extracellular Flux Analyzer (Seahorse
Bioscience). For OCR measurements, cells were seeded in four replicate wells
on Seahorse XF24 cell culture plates in their standard growth media and
assayed 24 h later. Two basal OCR measurements were taken in 9-min in-
tervals, followed by sequential injections of 1 μM oligomycin, 4 μM FCCP, and
1 μM antimycin A, taking two measurements at 9-min intervals following
each treatment. Following analysis, the cells were trypsinized and counted
for each well to normalize the OCR values. For basal ECAR measurements,
cells were seeded in four replicate wells on Seahorse XF24 cell culture plates
in their standard growth media, but lacking pyruvate. ECAR measurements
were performed 24 h later after starving of glucose for 1 h and restimulation
with 25 mM glucose for 35 min before the measurement. ECAR values were
normalized to cell numbers.
SYTOX Assay (Cell Death). Cell death assessment was performed using SYTOX
staining (100 nM, SYTOX Green; Molecular Probes) followed by FACS analysis
tomeasure relative SYTOX-positive cells as a function of total cells at 96 h post
doxycycline induction of the indicated lentiviral shRNAs.
Cell Counting (with Trypan Blue Staining). Following 96 h of propagation in the
absence or presence of doxycycline (to induce shRNA expression), cells were
trypsinized and analyzed on the ViCell Analyzer for total cell numbers and
percent of viable cells (Beckman). Trypan blue exclusion was used as an in-
dicator of cell viability.
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Cell-Cycle Analysis. Following 72 h of propagation in the presence of doxycycline
(to induce shRNA expression), BrdUwas added for 2 h, after which the cells where
trypsinized and stained with anti–BrdU-FITC antibody and 7AAD, following the
manufacturer’s protocol (BD Pharmingen catalog no. 559619). The cells were then
analyzed on a BD FACS Canto instrument and analyzed using FlowJo software.
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